Michael H Bernstein1, Maayan Rosenfield2, Nathaniel Fuchs2, Molly Magill2, Charlotte R Blease3, Francesca L Beaudoin4, Josiah D Rich5, Karolina Wartolowska6, Richard M Terek7. 1. School of Public Health, Brown University, Center for Alcohol & Addiction Studies, United States of America. Electronic address: Michael_Bernstein@brown.edu. 2. School of Public Health, Brown University, Center for Alcohol & Addiction Studies, United States of America. 3. General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Harvard Medical School, United States of America. 4. Department of Emergency Medicine, The Warren Alpert Medical School of Brown University, United States of America; Rhode Island Hospital & The Miriam Hospital, United States of America. 5. School of Public Health, Brown University, Center for Alcohol & Addiction Studies, United States of America; Warren Alpert Medical School of Brown University, United States of America. 6. Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom. 7. Warren Alpert Medical School of Brown University, United States of America.
Abstract
OBJECTIVE: To examine attitudes of Open Label Placebos (OLP) among a national sample of US orthopedic surgeons. METHODS: Orthopedic surgeons across the US were invited to participate in a brief online cross-sectional survey; n = 687 participated. The survey included a short vignette of a surgeon using adjunctive OLPs in addition to opioids for postoperative pain management. Participants indicated how ethical and effective they thought OLPs would be in this context, and whether they would personally consider using OLPs. RESULTS: Nearly three-quarters (73.9%) of the surgeons considered OLPs ethical. In total, 55.4% and 48.8% of participants said that OLPs would "probably" or "definitely" be effective for Vicodin reduction and pain relief, respectively. However, only 19.2% of participants indicated they were personally willing to consider OLPs, and 59.6% were unwilling to do so. CONCLUSIONS: Generally, orthopedic surgeons perceive OLPs as both ethical and effective, but would not consider using them in their practice. Further research is needed to identify clinician barriers to OLP use.
OBJECTIVE: To examine attitudes of Open Label Placebos (OLP) among a national sample of US orthopedic surgeons. METHODS: Orthopedic surgeons across the US were invited to participate in a brief online cross-sectional survey; n = 687 participated. The survey included a short vignette of a surgeon using adjunctive OLPs in addition to opioids for postoperative pain management. Participants indicated how ethical and effective they thought OLPs would be in this context, and whether they would personally consider using OLPs. RESULTS: Nearly three-quarters (73.9%) of the surgeons considered OLPs ethical. In total, 55.4% and 48.8% of participants said that OLPs would "probably" or "definitely" be effective for Vicodin reduction and pain relief, respectively. However, only 19.2% of participants indicated they were personally willing to consider OLPs, and 59.6% were unwilling to do so. CONCLUSIONS: Generally, orthopedic surgeons perceive OLPs as both ethical and effective, but would not consider using them in their practice. Further research is needed to identify clinician barriers to OLP use.
Authors: Kelsey M Flowers; Megan E Patton; Valerie J Hruschak; Kara G Fields; Emily Schwartz; Jose Zeballos; James D Kang; Rob R Edwards; Ted J Kaptchuk; Kristin L Schreiber Journal: Pain Date: 2021-06-01 Impact factor: 6.961
Authors: Leon Morales-Quezada; Ines Mesia-Toledo; Anayali Estudillo-Guerra; Kevin C O'Connor; Jeffrey C Schneider; Douglas J Sohn; David M Crandell; Ted Kaptchuk; Ross Zafonte Journal: Pain Rep Date: 2020-07-20